Moreover, the Japanese group retrospectively analyzed 25 FLT3-mutated R/R AML patients who received HSCT (14 patients received gilteritinib as maintenance therapy and 11 patients did not). This evidence concerns the gene FLT3 and acute myeloid leukemia.